NCT03478995: Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated, active, or progressing CNS metastases, or active CNS metastases requiring treatment- see trial for details

Comments are closed.

Up ↑